Clinical trial / 2001
Lycopene before prostatectomy reduced margin involvement and showed non-significant biomarker trends
In 26 men with localized prostate cancer, taking 15 mg of lycopene twice daily for 3 weeks resulted in 73% having clear margins or extra-prostatic tissue compared with 18% in controls (P = 0.02). Tumors under 4 ml occurred in 84% versus 45% (P = 0.22), and diffuse high-grade neoplasia occurred in 67% versus 100% (P = 0.05). PSA declined 18% with lycopene and rose 14% without, but IGF-1 decreased in both groups.
- Study type
- Randomized controlled trial
- Who was studied
- 26 men with newly diagnosed localized prostate cancer
- What was measured
- Surgical margin involvement, tumor size, and plasma prostate biomarkers
THE PAPER
Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy.
Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, Li YW, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP. Cancer Epidemiol Biomarkers Prev, 2001.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.